CROSS-REACTIVITY OF FUNGAL ALLERGENS

真菌过敏原的交叉反应

• 批准号: 2517250
• 负责人: ANUPMA B DIXIT
• 金额: $ 10.17万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-15 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2517250
• 关键词: allergens; biological products; cross immunity; enzyme linked immunosorbent assay; fungal antigens; genetic strain; immunoaffinity chromatography; immunoglobulin E; microorganism culture; molecular cloning; monoclonal antibody; morphology; protein sequence; spores; western blottings

DESCRIPTION (Adapted from applicant's abstract): The fungal spores are a major cause of seasonal and perennial allergic disease affecting approximately 30 percent of atopic individuals. Since sensitization to multiple fungi is common, the ultimate choice of allergens for diagnosis and treatment of mold sensitivity will depend upon the identification of individual allergens. The characterization of the individual fungal allergens is made more critical by prior studies suggesting cross-reactivity among allergens from many genera. The investigator has proposed to study the allergenic composition and relationships of selected aerobiologically and immunologically significant Fungi Imperfecti, especially dark spore formers. Fungi will be established in the laboratory under defined culture conditions. Extracts will be prepared from spores and mycelia. Clinical, biochemical, molecular biological and immunological investigations will follow in order to identify, purify and fully characterize the allergens. Allergenic proteins will be recognized by binding of the IgE present in sensitive patients' sera. The allergen profile of each fungus will be determined on the basis of allergenic composition of spore and mycelial extracts of at least three strains. General cross-reactivity of mold pairs will be recognized by ELISA-inhibition. Individual cross-reacting allergens present in various genera will be identified by immunoblotting and immunoprint inhibition. Further efforts will be focused on characterizing one or more major, including cross-reactive, allergens and on establishing homologies using physicochemical and immunological criteria, amino acid sequence data, monoclonal antibodies and molecular cloning. Eventually, this study will determine the allergenicity of purified allergen(s) among the patients. The availability of major cross-reactive allergens in pure and standardized states will greatly improve the diagnosis and treatment of allergies to the Fungi Imperfecti.

描述（改编自申请人的摘要）：真菌孢子 是影响季节性和常年性过敏性疾病的主要原因 大约 30% 的特应性个体。 自从敏化 对多种真菌的过敏很常见，过敏原的最终选择 霉菌敏感性的诊断和治疗取决于 识别个体过敏原。的表征 先前的研究使个别真菌过敏原变得更加重要 表明许多属的过敏原之间存在交叉反应。这 研究人员提议研究过敏成分和 所选空气生物学和免疫学的关系 显着的真菌不完美，尤其是深色孢子形成者。真菌会 在规定的培养条件下在实验室中建立。 提取物将从孢子和菌丝体中制备。临床， 生化、分子生物学和免疫学研究 接下来将识别、纯化并充分表征 过敏原。 过敏性蛋白质将通过结合来识别 IgE 存在于敏感患者的血清中。每个的过敏原概况 真菌将根据致敏成分来确定 至少三种菌株的孢子和菌丝提取物。 一般的 模具对的交叉反应性将通过 ELISA 抑制来识别。 不同属中存在的个体交叉反应过敏原会 通过免疫印迹和免疫印迹抑制来鉴定。更远 努力将集中于描述一个或多个专业的特征，包括 交叉反应、过敏原以及使用建立同源性 理化和免疫学标准、氨基酸序列数据、 单克隆抗体和分子克隆。最终，这项研究 将确定纯化过敏原的过敏原性 患者。主要交叉反应性过敏原在纯和 标准化状态将大大改善诊断和治疗 对不完美真菌过敏。